Compare PLX & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLX | OSUR |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.9M | 177.2M |
| IPO Year | 1998 | 1986 |
| Metric | PLX | OSUR |
|---|---|---|
| Price | $1.71 | $2.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $3.00 |
| AVG Volume (30 Days) | 570.7K | ★ 800.2K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $61,840,000.00 | ★ $125,703,000.00 |
| Revenue This Year | $14.53 | N/A |
| Revenue Next Year | $75.77 | $4.32 |
| P/E Ratio | $24.25 | ★ N/A |
| Revenue Growth | ★ 35.41 | N/A |
| 52 Week Low | $1.32 | $2.08 |
| 52 Week High | $3.10 | $4.22 |
| Indicator | PLX | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 51.76 |
| Support Level | $1.71 | $2.33 |
| Resistance Level | $1.86 | $2.47 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 16.67 | 85.71 |
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.